<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117444</article-id><article-id pub-id-type="publisher-id">ACM-43870</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_91930780.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  蛋白酪氨酸磷酸酶相互作用蛋白51的研究进展
  Protein Tyrosine Phosphatase Interacting Protein 51 Research Progress
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>于</surname><given-names>群</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>海鹏</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>文博</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>怀龙</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>时</surname><given-names>飞</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>潍坊医学院麻醉学院，山东 潍坊</addr-line></aff><aff id="aff4"><addr-line>烟台市烟台山医院麻醉科，山东 烟台</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属青岛市市立医院麻醉科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>3062</fpage><lpage>3069</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  蛋白酪氨酸磷酸酶相互作用蛋白51 (PTPIP51)是一种进化保守的新型线粒体蛋白，在哺乳动物中广泛表达，与多种蛋白结合参与细胞信号通路的传递，是各项生命活动正常进行的基础，多种疾病的发生都与PTPIP51的表达异常有关。本文就PTPIP51的生物学特性、在细胞周期中的作用、与细胞凋亡和自噬、与肿瘤和神经退行性疾病的关系以及在记忆中的作用等研究做一综述。
   Protein tyrosine phosphatase interacting protein 51 (PTPIP51) is an evolutionarily conserved new type of mitochondrial protein widely expressed in mammals. Binding to multiple proteins to participate in the transmission of cellular signaling pathways is the basis for the normal conduct of various life activities. The occurrence of multiple diseases is all related to the abnormal expression of PTPIP51. This review focuses on the biological characteristics of PTPIP51, its role in the cell cycle, its association with apoptosis and autophagy, with tumor and neurodegenerative diseases, and in memory.
 
</p></abstract><kwd-group><kwd>蛋白酪氨酸磷酸酶相互作用蛋白51，MAPK途径，细胞凋亡，肿瘤，线粒体–内质网结构偶联, Protein Tyrosine Phosphatase Interacting Protein 51</kwd><kwd> MAPK Pathway</kwd><kwd> Apoptosis</kwd><kwd> Tumor</kwd><kwd> 
Mitochondria-Associated Endoplasmic Reticulum Membranes</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>蛋白酪氨酸磷酸酶相互作用蛋白51 (PTPIP51)是一种进化保守的新型线粒体蛋白，在哺乳动物中广泛表达，与多种蛋白结合参与细胞信号通路的传递，是各项生命活动正常进行的基础，多种疾病的发生都与PTPIP51的表达异常有关。本文就PTPIP51的生物学特性、在细胞周期中的作用、与细胞凋亡和自噬、与肿瘤和神经退行性疾病的关系以及在记忆中的作用等研究做一综述。</p></sec><sec id="s2"><title>关键词</title><p>蛋白酪氨酸磷酸酶相互作用蛋白51，MAPK途径，细胞凋亡，肿瘤，线粒体–内质网结构偶联</p></sec><sec id="s3"><title>Protein Tyrosine Phosphatase Interacting Protein 51 Research Progress<sup> </sup></title><p>Qun Yu<sup>1</sup>, Haipeng Wang<sup>2</sup>, Wenbo Zhang<sup>3</sup>, Huailong Chen<sup>2</sup>, Fei Shi<sup>2*</sup></p><p><sup>1</sup>Department of Anesthesiology, Weifang Medical College, Weifang Shandong</p><p><sup>2</sup>Department of Anesthesiology, Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao Shandong</p><p><sup>3</sup>Department of Anesthesiology, Yantaishan Hospital, Yantai Shandong</p><p><img src="//html.hanspub.org/file/25-1572370x4_hanspub.png?20210715080317642" /></p><p>Received: Jun. 9<sup>th</sup>, 2021; accepted: Jul. 1<sup>st</sup>, 2021; published: Jul. 14<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/25-1572370x5_hanspub.png?20210715080317642" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Protein tyrosine phosphatase interacting protein 51 (PTPIP51) is an evolutionarily conserved new type of mitochondrial protein widely expressed in mammals. Binding to multiple proteins to participate in the transmission of cellular signaling pathways is the basis for the normal conduct of various life activities. The occurrence of multiple diseases is all related to the abnormal expression of PTPIP51. This review focuses on the biological characteristics of PTPIP51, its role in the cell cycle, its association with apoptosis and autophagy, with tumor and neurodegenerative diseases, and in memory.</p><p>Keywords:Protein Tyrosine Phosphatase Interacting Protein 51, MAPK Pathway, Apoptosis, Tumor, Mitochondria-Associated Endoplasmic Reticulum Membranes</p><disp-formula id="hanspub.43870-formula17"><graphic xlink:href="//html.hanspub.org/file/25-1572370x7_hanspub.png?20210715080317642"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/25-1572370x8_hanspub.png?20210715080317642" /> <img src="//html.hanspub.org/file/25-1572370x9_hanspub.png?20210715080317642" /></p></sec><sec id="s5"><title>1. 引言</title><p>蛋白酪氨酸磷酸酶相互作用蛋白(protein tyrosine phosphatase interacting protein, PTPIP) 51属于与微管细胞骨架相互作用的蛋白质家族，也称为微管相关蛋白，最初被描述为两种非受体酪氨酸磷酸酶的相互作用伴侣，即蛋白质酪氨酸磷酸酶1B (protein tyrosine phosphatase 1B, PTP1B)和T细胞蛋白质酪氨酸磷酸酶(T-cell protein tyrosine phosphatase, TCPTP) [<xref ref-type="bibr" rid="hanspub.43870-ref1">1</xref>] 现在被认为是形成多种复合物的新支架蛋白，干扰许多细胞进程 [<xref ref-type="bibr" rid="hanspub.43870-ref2">2</xref>]。</p></sec><sec id="s6"><title>2. PTPIP51的结构</title><p>PTPIP51由三个专门称为微管动力学调节器(RMD)的成员组成，分别称为RMD1、RMD2和RMD3 [<xref ref-type="bibr" rid="hanspub.43870-ref3">3</xref>]。PTPIP51的基因名称以具有序列相似性82 (FAM82)的B family的名称概括，每个基因由三个成员组成，都有其特定的后缀。对于PTPIP51，它是FAM82A2，该基因在人类基因组中位于染色体15q15.1上，涵盖13个外显子和12个内含子，跨度接近20 kb。PTPIP51 (NM018145)的cDNA为2251个碱基对长，包含5端的ATG启动密码子和3末端的poly (A)信号序列，其mRNA存在于人、猩猩、小鼠、大鼠、狗、鸡和青蛙的组织中，包括大脑、小脑、小肠、肾脏、肝脏、肺、骨骼肌、胰腺和脾脏 [<xref ref-type="bibr" rid="hanspub.43870-ref4">4</xref>]，在其蛋白质的N端附近有一个保守的跨膜结构域(transmembrane domain, TM)，该结构域是由N端的第1~30位氨基酸组成的一个跨膜的螺旋结构，在C末端有结合靶蛋白的位点，该位点是由两个反向平行的α螺旋结构串联排列而成 [<xref ref-type="bibr" rid="hanspub.43870-ref5">5</xref>]。因此，PTPIP51被认为是一种进化保守蛋白 [<xref ref-type="bibr" rid="hanspub.43870-ref3">3</xref>]。</p></sec><sec id="s7"><title>3. PTPIP51的生理功能</title><sec id="s7_1"><title>3.1. PTPIP51在细胞周期中的变化</title><p>在有丝分裂过程中，Raf-1受到RAF激酶抑制蛋白(RKIP)的严格调控，该蛋白会滴定有丝分裂原激活的蛋白激酶(MAPK)途径的信号，从而确保正常的染色体分离。PTPIP51在Raf-1水平上与MAPK途径相关，PTPIP51通过与14-3-3蛋白相互作用并形成PTPIP51/14-3-3/Raf-1复合物来激活Raf-1上的ERK [<xref ref-type="bibr" rid="hanspub.43870-ref6">6</xref>]，这些作用受PTPIP51酪氨酸磷酸化状态的调节，PTPIP51的过度磷酸化抑制了其与14-3-3蛋白和Raf-1的相互作用 [<xref ref-type="bibr" rid="hanspub.43870-ref7">7</xref>]。有趣的是，在有丝分裂后分裂细胞中，PTPIP51/PTP1B的相互作用大大增强，这种相互作用被认为是酶–底物复合物的相互作用 [<xref ref-type="bibr" rid="hanspub.43870-ref2">2</xref>]。因此，PTP1B在其酪氨酸176残基处使PTPIP51脱磷酸化，以充当相间细胞中MAPK途径的调节剂，以确保有丝分裂的能量供应。在急性髓细胞性白血病(AML)的细胞中也观察到酪氨酸磷酸化的PTPIP51含量很高，使这些白血病细胞具有高度的有丝分裂指数 [<xref ref-type="bibr" rid="hanspub.43870-ref8">8</xref>]。因此，磷酸化的PTPIP51可能参与正常细胞以及癌细胞的增殖过程。</p><p>RMD-1也在有丝分裂过程中起着关键作用，特别是在染色体的正确分离中，只有PTPIP51在分裂时提供完整的纺锤体，才能实现无错误的染色体分离 [<xref ref-type="bibr" rid="hanspub.43870-ref9">9</xref>]。</p></sec><sec id="s7_2"><title>3.2. PTPIP51与细胞凋亡</title><p>凋亡是至关重要的细胞过程，它是由特定基因调控的细胞自主有序的死亡，可清除多余、受损或感染的细胞来维持组织稳态，对生物体正常生命活动至关重要 [<xref ref-type="bibr" rid="hanspub.43870-ref10">10</xref>]。PTPIP51过表达的细胞显示出明显的细胞凋亡的特征 [<xref ref-type="bibr" rid="hanspub.43870-ref11">11</xref>]：核浓缩，磷脂酰丝氨酸(PS)外部化，线粒体跨膜电位去极化，细胞色素c释放，并激活caspase-3。同时发现，PTPIP51的过表达可以诱导线粒体跨膜电位去极化和细胞色素c的释放，这表明PTPIP51参与了线粒体/细胞色素c介导的凋亡途径。此外，PTPIP51的N末端TM结构域可作为凋亡调控中的关键结构域，在蛋白质靶向线粒体中起作用，N末端截短的突变体PTPIP51-TM的线粒体定位丧失，极大地影响了其诱导凋亡的能力 [<xref ref-type="bibr" rid="hanspub.43870-ref4">4</xref>]，但其触发的信号通路还需要做进一步的研究。</p></sec><sec id="s7_3"><title>3.3. PTPIP51与细胞自噬</title><p>内质网与线粒体在细胞内广泛分布，是维持细胞功能的重要细胞器。随着电镜成像技术的进步，人们发现线粒体外膜与内质网膜间存在高度共定位，但彼此之间不融合，保持较稳定的膜间距，称为线粒体–内质网结构偶联(MAMs)，MAMs对两个细胞器间功能的“协作”具有重要作用，是线粒体和内质网发生交互作用的功能平台，与脂质代谢、钙信号传导、内质网应激以及线粒体形态调节等密切相关 [<xref ref-type="bibr" rid="hanspub.43870-ref12">12</xref>]。定位于线粒体外膜的PTPIP51与定位于内质网膜的囊泡相关膜蛋白相关蛋白B (vesicle-associated membrane protein-associated protein B, VAPB)结合，构成MAMs的一条重要通路，主要参与调控细胞自噬。</p><p>在缺血再灌注细胞中，PTPIP51蛋白表达上调，线粒体内质网膜的接触率增加，通过线粒体钙单向转运蛋白(MCU)增加Ca<sup>2+</sup>从内质网到线粒体的转移，从而引起线粒体Ca<sup>2+</sup>超负荷并最终导致细胞死亡 [<xref ref-type="bibr" rid="hanspub.43870-ref13">13</xref>]。当在心肌细胞中下调PTPIP51的表达可防止H<sub>2</sub>O<sub>2</sub>诱导的心肌细胞凋亡或I/R诱导的心脏损伤 [<xref ref-type="bibr" rid="hanspub.43870-ref14">14</xref>]。尚不清楚调节PTPIP51蛋白水平是否引起调节性心脏保护作用，但是，更好地了解PTPIP51表达的调节机制可能有助于开发PTPIP51相关的心脏保护策略以及细胞缺血再灌注引起的损伤。</p><p>在肺囊性纤维化导致的炎症中，铜绿假单胞菌感染通过影响VAPB-PTPIP51增加囊性纤维化支气管细胞内质网–线粒体的联系，影响自噬，从而诱导线粒体展开蛋白反应和NLRP3炎症小体激活，导致过度炎症。VAPB-PTPIP51调节囊性纤维化细胞自噬的机制与MCU有关，MCU抑制可纠正自噬，减轻体内外炎症反应，从而成为囊性纤维化肺疾病的有效治疗策略 [<xref ref-type="bibr" rid="hanspub.43870-ref15">15</xref>]。</p></sec></sec><sec id="s8"><title>4. PTPIP51与疾病的关系</title><sec id="s8_1"><title>4.1. PTPIP51与肿瘤</title><p>MAPK途径是癌症中最常见的信号系统之一，在所有人类癌症中，几乎有三分之一报告了MAPK信号转导的改变，这表明对该途径的研究较为成熟 [<xref ref-type="bibr" rid="hanspub.43870-ref16">16</xref>]。以下介绍PTPIP51在几种不同疾病的失调的MAPK信号通路中的中心地位。</p><sec id="s8_1_1"><title>4.1.1. 乳腺癌</title><p>乳腺癌是女性中最常见的肿瘤，约占所有诊断出的肿瘤的25%，大约三分之一的乳腺肿瘤表现出HER2/ErbB2受体的过表达，这导致癌细胞更具侵略性和侵袭性的生长，从而损害了整体生存时间 [<xref ref-type="bibr" rid="hanspub.43870-ref17">17</xref>]。Her2受体的扩增诱导主要有两个不同的信号通路：MAPK通路和AKT信号通路的过度激活 [<xref ref-type="bibr" rid="hanspub.43870-ref18">18</xref>]。PTPIP51在正常的乳腺以及乳腺癌细胞中都有表达，但乳腺癌细胞中的磷酸化强烈上调。Tyr176残基的磷酸化通过14-3-3调节PTPIP51与Raf-1的结合，从而发挥其MAPK刺激作用 [<xref ref-type="bibr" rid="hanspub.43870-ref7">7</xref>]。PTPIP51的下调与Tyr176残基的高磷酸化相结合，显示了PTPIP51在乳腺癌细胞中对MAPK刺激作用的潜在抑制作用。因此，PTPIP51的调节似乎抵消了促进MAPK信号传导的肿瘤的激活 [<xref ref-type="bibr" rid="hanspub.43870-ref19">19</xref>]。</p><p>PTPIP51也与Her2受体相互作用，用TKI Mubritinib选择性抑制Her2受体可诱导形成由Her2受体、PTPIP51和c-Src组成的潜在三元复合物Her2/c-Src/PTPIP51 [<xref ref-type="bibr" rid="hanspub.43870-ref20">20</xref>]。而c-Src在Her2靶向治疗耐药性以及生长和生存信号的转导中起着至关重要的作用 [<xref ref-type="bibr" rid="hanspub.43870-ref21">21</xref>]。三元复合物的形成强调了PTPIP51在这些抗性机制介导中的关键作用 [<xref ref-type="bibr" rid="hanspub.43870-ref20">20</xref>]。表明PTPIP51的一个潜在作用是在肿瘤中促进了靶向KI/EGFR靶向TKI的信号传导和治疗耐药性 [<xref ref-type="bibr" rid="hanspub.43870-ref22">22</xref>]。</p></sec><sec id="s8_1_2"><title>4.1.2. 胶质母细胞瘤</title><p>胶质母细胞瘤(GBM)是成人中最常见的原发性脑肿瘤，几乎占所有原发性脑肿瘤的80% [<xref ref-type="bibr" rid="hanspub.43870-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.43870-ref24">24</xref>]，研究发现该肿瘤有三种最常激活的信号传导途径，分别是p53信号传导、成视网膜细胞瘤途径和受体酪氨酸激酶-Ras-PI3K途径 [<xref ref-type="bibr" rid="hanspub.43870-ref25">25</xref>]。GBM中有一种特殊的受体酪氨酸激酶EGFR，其组成性激活的突变体是EGFRvIII。在所有GBM中约有30%发生这种突变 [<xref ref-type="bibr" rid="hanspub.43870-ref24">24</xref>]。EGFRvIII导致MAPK途径的过度激活，从而导致过度的生长和生存信号传递 [<xref ref-type="bibr" rid="hanspub.43870-ref6">6</xref>]。PTPIP51是EGFRvIII和支架蛋白14-3-3之间的可能功能连接，其蛋白结构包括两个保守区域，有助于与14-3-3蛋白结合 [<xref ref-type="bibr" rid="hanspub.43870-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.43870-ref26">26</xref>]。此外，这些位点还伴有丝氨酸和酪氨酸残基，其磷酸化控制PTPIP51和14-3-3的结合 [<xref ref-type="bibr" rid="hanspub.43870-ref3">3</xref>]。因此，在高恶性胶质瘤中，通过PTPIP51与14-3-3蛋白的结合，可探索潜在的抗凋亡机制。</p><p>同乳腺癌研究中的发现一样，PTPIP51和c-Src的相互作用可能构成了抗EGFR治疗耐药性的肿瘤间机制 [<xref ref-type="bibr" rid="hanspub.43870-ref19">19</xref>]。</p></sec><sec id="s8_1_3"><title>4.1.3. 黑色素瘤</title><p>黑色素瘤约占皮肤癌的2%，但占死亡率的75%至90% [<xref ref-type="bibr" rid="hanspub.43870-ref27">27</xref>]，显示出所有癌症中最高的突变频率 [<xref ref-type="bibr" rid="hanspub.43870-ref28">28</xref>]。对于黑色素瘤的发病机理，MAPK途径的激活至关重要 [<xref ref-type="bibr" rid="hanspub.43870-ref29">29</xref>]，且其激活突变会导致组成性激活BRAF激酶。尽管黑色素细胞的分子特征发生了巨大变化，从正常痣到发育不良痣，再到恶性黑色素细胞，但在这些不同阶段，PTPIP51蛋白的量没有显着变化，但是发现，如果Tyr176处去磷酸化时，PTPIP51能与RAF或14-3-3蛋白结合，从而促进MAPK信号传导，加速其恶化程度。同时发现，PTPIP51/BRAF相互作用在增生性痣黑色素细胞中最低，在黑色素瘤细胞中则较高，而在健康的黑色素细胞中最高，说明PTPIP51在去分化黑素细胞中具有反调节功能，抑制PTPIP51的RAF刺激作用可以用作对抗BRAF失调的反调节机制 [<xref ref-type="bibr" rid="hanspub.43870-ref19">19</xref>]。</p></sec><sec id="s8_1_4"><title>4.1.4. 急性髓细胞性白血病</title><p>急性髓细胞性白血病(AML)是高度恶性的肿瘤，在最近几年中表现出近乎稳定的发病率，每10万人有3.7例患病 [<xref ref-type="bibr" rid="hanspub.43870-ref30">30</xref>]。PTPIP51在AML中显示与疾病相关的同工型表达，但丢失了位于PTPIP51 N端部分的TM结构域 [<xref ref-type="bibr" rid="hanspub.43870-ref31">31</xref>]，这对于线粒体结合和PTPIP51的凋亡功能至关重要，但PTPIP51的MAPK结合能力的生理调节似乎是完整的。因此，小分子可以直接靶向PTPIP51涉及的信号分子，从而诱导AML原始细胞的凋亡。</p><p>在多种肿瘤组织和细胞系中均可发现PTPIP51的表达，除上述4种还包括角质形成细胞癌(即人基底细胞癌、鳞状细胞癌、Bowen 病及角化棘皮瘤)和HT29、HL20等细胞系，在肿瘤周围基质细胞也可以发现其表达 [<xref ref-type="bibr" rid="hanspub.43870-ref32">32</xref>]。PTPIP51在肿瘤组织和癌前环境中的表达，可能会促进肿瘤血管形成，且与肿瘤细胞增殖、迁移密切相关。</p></sec></sec><sec id="s8_2"><title>4.2. PTPIP51与神经退行性疾病</title><p>PTPIP51可在哺乳动物脑组织中表达 [<xref ref-type="bibr" rid="hanspub.43870-ref33">33</xref>]。细胞水平上，蛋白质和mRNA均与海马结构的锥体细胞、齿状回的粒状细胞以及相邻层的细胞有关，且在海马细胞中，检测到PTPIP51与VAPB的强相互作用 [<xref ref-type="bibr" rid="hanspub.43870-ref34">34</xref>]。在小脑中，PTPIP51表达于浦肯野细胞和树突状细胞亚群 [<xref ref-type="bibr" rid="hanspub.43870-ref33">33</xref>]，发现14-3-3、二酰基甘油激酶α (DGKα)、NFκB和PTP1B的相互作用水平较高，这些相互作用代表与记忆相关的特定信号传导途径。PTPIP51可能与神经生长因子信号传导，树突和轴突生长，突触形成以及记忆形成所需的所有过程有关。此外，在HT-22小鼠海马细胞中，成纤维细胞生长因子1 (FGF-1)参与学习/记忆过程。神经退行性疾病是一组原因不明的慢性进行性损害神经等组织的疾病。研究表明，神经退行性疾病中可发现包括钙离子分布紊乱、细胞凋亡水平提高、细胞自噬水平下降、轴突运输障碍以及炎症反应等现象 [<xref ref-type="bibr" rid="hanspub.43870-ref12">12</xref>]。</p><sec id="s8_2_1"><title>4.2.1. 帕金森病</title><p>帕金森病是人类第二大常见的神经退行性疾病，其特征是黑质中多巴胺能神经元的丢失，引起这种神经元丧失的细胞和分子事件尚未得到适当的理解，但是许多证据表明α-突触核蛋白的异常是疾病过程的核心 [<xref ref-type="bibr" rid="hanspub.43870-ref35">35</xref>]。研究发现，MAMs中存在一定比例的α-突触核蛋白，它可以与VAPB结合，破坏VAPB-PTPIP51相互作用并扰乱内质网–线粒体的关联 [<xref ref-type="bibr" rid="hanspub.43870-ref36">36</xref>]，从而影响两个细胞器之间的Ca<sup>2+</sup>交换和ATP生成障碍 [<xref ref-type="bibr" rid="hanspub.43870-ref37">37</xref>]，这揭示了α-突触核蛋白和帕金森病的新分子机制。</p></sec><sec id="s8_2_2"><title>4.2.2. 阿尔兹海默症</title><p>阿尔兹海默症(Alzheimer’s disease, AD)是一种隐匿发生且发展缓慢的神经退行性疾病，最初在一个多世纪前由德国神经精神病学家Dr. Alois Alzheimer发现，到如今已被认为是痴呆性疾病中最常见的类型 [<xref ref-type="bibr" rid="hanspub.43870-ref38">38</xref>]。其主要病理学特点是含有β-淀粉样蛋白(amyloid beta, Aβ)的细胞外神经炎性斑块和由过度磷酸化的tau蛋白组成的细胞内神经原纤维缠结的沉积。MAMs被认为是Aβ形成的主要部位 [<xref ref-type="bibr" rid="hanspub.43870-ref39">39</xref>]，与AD的发生发展密切相关，研究发现，在阿尔茨海默病晚期，VAPB-PTPIP51在颞叶皮层中降低，同时在死后阿尔茨海默病的皮层中，受累的锥体神经元中的VAPB-PTPIP51结构被破坏，且这种破坏发生在疾病的相对早期阶段 [<xref ref-type="bibr" rid="hanspub.43870-ref40">40</xref>]。这揭示了阿尔茨海默病的一种新的病理表型。</p><p>另有研究发现，应激线粒体的恢复是神经退行性变早期线粒体质量控制和能量维持的关键步骤，Mul1-Mfn2通路通过调控线粒体形态和MAMs，在维持线粒体完整性方面发挥早期作用 [<xref ref-type="bibr" rid="hanspub.43870-ref41">41</xref>]，MAMs中PTPIP51可增强内质网线粒体相互作用，这为应激条件下神经元线粒体维持揭示了新的机制，与几种主要的与线粒体功能障碍和MAMs改变相关的神经退行性疾病有关。</p></sec></sec></sec><sec id="s9"><title>5. 展望</title><p>PTPIP51作为一种新型的线粒体蛋白，与RAF、PTP1B、Src激酶以及VAPB等多种蛋白的结合，通过线粒体/细胞色素c通路、MAPK通路以及MAMs等多种通路参与生命活动的多个步骤，对机体维持正常的生理活动起到重要的作用。然而，目前对PTPIP51分子的研究尚不完全，许多机制还不清楚，在肿瘤中，PTPIP51可能通过MAPK途径与其他几个信号系统相连，如Akt和NF-B信号，参与恶性肿瘤的侵袭和转移，同时PTPIP51和c-Src的相互作用似乎与本文所述肿瘤的治疗耐药机制有很大关系，需要进一步研究。在神经退行性疾病中，PTPIP51可能通过改变MAMs进而扰乱突触活性，是将神经退行性疾病损害与突触功能障碍联系起来的新途径。所以，对PTPIP51分子具体机制的进一步研究会促进对其在疾病病理过程中的了解，为以后的疾病治疗提供相关的基础及潜在的靶分子。</p></sec><sec id="s10"><title>利益冲突</title><p>所有作者均声明不存在利益冲突。</p></sec><sec id="s11"><title>文章引用</title><p>于 群,王海鹏,张文博,陈怀龙,时 飞. 蛋白酪氨酸磷酸酶相互作用蛋白51的研究进展Protein Tyrosine Phosphatase Interacting Protein 51 Research Progress[J]. 临床医学进展, 2021, 11(07): 3062-3069. https://doi.org/10.12677/ACM.2021.117444</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43870-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Stenzinger, A., Kajosch, T., Tag, C., et al. (2005) The Novel Protein PTPIP51 Exhibits Tissue and Cell-Specific Expression. Histochemistry and Cell Biology, 123, 19-28. &lt;br&gt;https://doi.org/10.1007/s00418-004-0732-7</mixed-citation></ref><ref id="hanspub.43870-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Stenzinger, A., Schreiner, D., Koch, P., et al. (2009) Cell and Molecular Biology of the Novel Protein Tyrosine-Phosphatase-Interacting Protein 51. International Review of Cell and Molecular Biology, 275, 183-246.  
&lt;br&gt;https://doi.org/10.1016/S1937-6448(09)75006-3</mixed-citation></ref><ref id="hanspub.43870-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Brobeil, A., Bobrich, M. and Wimmer, M. (2011) Protein Tyrosine Phosphatase Interacting Protein 51—A Jack of All Trades Protein. Cell and Tissue Research, 344, 189-205. &lt;br&gt;https://doi.org/10.1007/s00441-011-1146-1</mixed-citation></ref><ref id="hanspub.43870-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Schwarzer, R., Laurien, L. and Pasparakis, M. (2020) New Insights into the Regulation of Apoptosis, Necroptosis, and Pyroptosis by Receptor Interacting Protein Kinase 1 and Caspase-8. Current Opinion in Cell Biology, 63, 186-193.  
&lt;br&gt;https://doi.org/10.1016/j.ceb.2020.02.004</mixed-citation></ref><ref id="hanspub.43870-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Leano, J.B. and Slep, K.C. (2019) Structures of TOG1 and TOG2 from the Human Microtubule Dynamics Regulator CLASP1. PLoS ONE, 14, e0219823. &lt;br&gt;https://doi.org/10.1371/journal.pone.0219823</mixed-citation></ref><ref id="hanspub.43870-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Yu, C., Han, W., Shi, T., et al. (2008) PTPIP51, a Novel 14-3-3 Binding Protein, Regulates Cell Morphology and Motility via Raf-ERK Pathway. Cell Signal, 20, 2208-2220. &lt;br&gt;https://doi.org/10.1016/j.cellsig.2008.07.020</mixed-citation></ref><ref id="hanspub.43870-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Brobeil, A., Bobrich, M., Tag, C., et al. (2012) PTPIP51 in Protein Interactions—Regulation and in Situ Interacting Partners. Cell Biochemistry and Biophysics, 63, 211-222. &lt;br&gt;https://doi.org/10.1007/s12013-012-9357-y</mixed-citation></ref><ref id="hanspub.43870-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hanoun, M., Zhang, D., Mizoguchi, T., et al. (2014) Acute Myelogenous Leukemia-Induced Sympathetic Neuropathy Promotes Malignancy in an Altered Hematopoietic Stem Cell Niche. Cell Stem Cell, 15, 365-375.  
&lt;br&gt;https://doi.org/10.1016/j.stem.2014.06.020</mixed-citation></ref><ref id="hanspub.43870-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Oishi, K., Okano, H. and Sawa, H. (2007) RMD-1, a Novel Microtubule-Associated Protein, Functions in Chromosome Segregation in Caenorhabditis elegans. Cell Biology, 179, 1149-1162. &lt;br&gt;https://doi.org/10.1083/jcb.200705108</mixed-citation></ref><ref id="hanspub.43870-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Benakanakere, M.R., Zhao, J., Finoti, L., et al. (2019) MicroRNA-663 Antagonizes Apoptosis Antagonizing Transcription Factor to Induce Apoptosis in Epithelial Cells. Apoptosis, 24, 108-118.  
&lt;br&gt;https://doi.org/10.1007/s10495-018-01513-9</mixed-citation></ref><ref id="hanspub.43870-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Lee, Y.S., Kalimuthu, K., Park, Y.S., et al. (2020) BAX-Dependent Mitochondrial Pathway Mediates the Crosstalk between Ferroptosis and Apoptosis. Apoptosis, 25, 625-631. &lt;br&gt;https://doi.org/10.1007/s10495-020-01627-z</mixed-citation></ref><ref id="hanspub.43870-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">肖玉霞. 蛋白酪氨酸磷酸酶相互作用蛋白51的研究进展[J]. 国际口腔医学杂志, 2012, 39(5): 679-682.</mixed-citation></ref><ref id="hanspub.43870-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Gomez-Suaga, S., Paillusson, R., Stoica, W., et al. (2017) The ER-Mitochondria Tethering Complex VAPB-PTPIP51 Regulates Autophagy. Current Biology, 27, 371-385. &lt;br&gt;https://doi.org/10.1016/j.cub.2016.12.038</mixed-citation></ref><ref id="hanspub.43870-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Qiao, X., Jia, S., Ye, J., et al. (2017) PTPIP51 Regulates Mouse Cardiac Ischemia/Reperfusion through Mediating the Mitochondria-SR Junction. Scientific Reports, 7, Article No. 45379. &lt;br&gt;https://doi.org/10.1038/srep45379</mixed-citation></ref><ref id="hanspub.43870-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Rimessi, A., Pozzato, C., Carparelli, L., et al. (2020) Pharmacological Modulation of Mitochondrial Calcium Uniporter Controls Lung Inflammation in Cystic Fibrosis. Science Advances, 6, eaax9093.  
&lt;br&gt;https://doi.org/10.1126/sciadv.aax9093</mixed-citation></ref><ref id="hanspub.43870-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Z., Zhu, G., Getzenberg, R.H., et al. (2015) The Upregulation of PI3K/Akt and MAP Kinase Pathways Is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer. Journal of Cellular Biochemistry, 116, 1341-1349. &lt;br&gt;https://doi.org/10.1002/jcb.25091</mixed-citation></ref><ref id="hanspub.43870-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Antolín-Novoa, S., Blanco-Campanario, E., Antón, A., et al. (2015) Adjuvant Regimens with Trastuzumab Administered for Small HER2-Positive Breast Cancer in Routine Clinical Practice. Clinical and Translational Oncology, 17, 862-869. &lt;br&gt;https://doi.org/10.1007/s12094-015-1316-9</mixed-citation></ref><ref id="hanspub.43870-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Moasser, M.M. (2007) The Oncogene HER2: Its Signaling and Transforming Functions and Its Role in Human Cancer Pathogenesis. Oncogene, 26, 6469-6487. &lt;br&gt;https://doi.org/10.1038/sj.onc.1210477</mixed-citation></ref><ref id="hanspub.43870-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Dietel, E., Brobeil, A. and Gattenlöhner, S. (2018) The Importance of the Right Framework: Mitogen-Activated Protein Kinase Pathway and the Scaffolding Protein PTPIP51. International Journal of Molecular Sciences, 19, 3282.  
&lt;br&gt;https://doi.org/10.3390/ijms19103282</mixed-citation></ref><ref id="hanspub.43870-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Dietel, E., Brobeil, A., Tag, C., et al. (2018) Effectiveness of EGFR/HER2-Targeted Drugs Is Influenced by the Downstream Interaction Shifts of PTPIP51 in HER2-Amplified Breast Cancer Cells. Oncogenesis, 7, 64.  
&lt;br&gt;https://doi.org/10.1038/s41389-018-0075-1</mixed-citation></ref><ref id="hanspub.43870-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Peiró, G., Ortiz-Martínez, F., Gallardo, M.A., et al. (2014) Src, a Potential Target for Overcoming Trastuzumab Resistance in HER2-Positive Breast Carcinoma. British Journal of Cancer, 111, 689-695.  
&lt;br&gt;https://doi.org/10.1038/bjc.2014.327</mixed-citation></ref><ref id="hanspub.43870-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Dietel, E., Brobeil, A., Tag, C., et al. (2020) PTPIP51 Crosslinks the NFκB Signaling and the MAPK Pathway in SKBR3 Cells. Future Science OA, 6, FSO463. &lt;br&gt;https://doi.org/10.2144/fsoa-2019-0136</mixed-citation></ref><ref id="hanspub.43870-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Davis, M.E. (2016) Glioblastoma: Overview of Disease and Treatment. Clinical Journal of Oncology Nursing, 20, S2-S8. &lt;br&gt;https://doi.org/10.1188/16.CJON.S1.2-8</mixed-citation></ref><ref id="hanspub.43870-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Jovčevska, I., Kočevar, N. and Komel, R. (2013) Glioma and Glioblastoma—How Much Do We (Not) Know? Molecular and Clinical Oncology, 1, 935-941. &lt;br&gt;https://doi.org/10.3892/mco.2013.172</mixed-citation></ref><ref id="hanspub.43870-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Verhaak, R.G., Hoadley, K.A., Purdom, E., et al. (2010) Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17, 98-110. &lt;br&gt;https://doi.org/10.1016/j.ccr.2009.12.020</mixed-citation></ref><ref id="hanspub.43870-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Loew, S., Schmidt, U., Unterberg, A. and Halatsch, M. (2009) The Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma Multiforme and Other Malignant Neoplasms. Anti-Cancer Agents in Medicinal Chemistry, 9, 703-715. &lt;br&gt;https://doi.org/10.2174/187152009788680019</mixed-citation></ref><ref id="hanspub.43870-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Chan, X.Y., Singh, A., Osman, N., et al. (2017) Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma. International Journal of Molecular Sciences, 18, E1527.  
&lt;br&gt;https://doi.org/10.3390/ijms18071527</mixed-citation></ref><ref id="hanspub.43870-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Davis, E.J., Johnson, D.B., Sosman, J.A. and Chandra, S. (2018) Melanoma: What Do All the Mutations Mean? Cancer, 124, 3490-3499. &lt;br&gt;https://doi.org/10.1002/cncr.31345</mixed-citation></ref><ref id="hanspub.43870-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Amaral, T., Sinnberg, T., Meier, F., et al. (2017) The Mitogen-Activated Protein Kinase Pathway in Melanoma Part I—Activation and Primary Resistance Mechanisms to BRAF Inhibition. European Journal of Cancer, 73, 85-92.  
&lt;br&gt;https://doi.org/10.1016/j.ejca.2016.12.010</mixed-citation></ref><ref id="hanspub.43870-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Kantarjian, H., Brien, S., Jabbour, E., et al. (2012) Improved Survival in Chronic Myeloid Leukemia since the Introduction of Imatinib Therapy: A Single-Institution Historical Experience. Blood, 119, 1981-1987.  
&lt;br&gt;https://doi.org/10.1182/blood-2011-08-358135</mixed-citation></ref><ref id="hanspub.43870-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Brobeil, A., Bobrich, M., Graf, M., et al. (2011) PTPIP51 Is Phosphorylated by Lyn and c-Src Kinases Lacking Dephosphorylation by PTP1B in Acute Myeloid Leukemia. Leukemia Research, 35, 1367-1375.  
&lt;br&gt;https://doi.org/10.1016/j.leukres.2011.03.024</mixed-citation></ref><ref id="hanspub.43870-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Koch, P., Stenzinger, A., Viard, M., et al. (2008) The Novel Protein PTPIP51 Is Expressed in Human Keratinocyte Carcinomas and Their Surrounding Stroma. Journal of Cellular and Molecular Medicine, 12, 2083-2095.  
&lt;br&gt;https://doi.org/10.1111/j.1582-4934.2008.00198.x</mixed-citation></ref><ref id="hanspub.43870-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Koch, P., Viard, M., Stenzinger, A., et al. (2009) Expression Profile of PTPIP51 in Mouse Brain. The Journal of Comparative Neurology, 517, 892-905. &lt;br&gt;https://doi.org/10.1002/cne.22201</mixed-citation></ref><ref id="hanspub.43870-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Brobeil, A., Viard, M., Petri, M.K., et al. (2015) Memory and PTPIP51-A New Protein in Hippocampus and Cerebellum. Molecular and Cellular Neuroscience, 64, 61-73. &lt;br&gt;https://doi.org/10.1016/j.mcn.2014.12.003</mixed-citation></ref><ref id="hanspub.43870-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Appel-Cresswell, S., Vilarino-Guell, C., Encarnacion, M., et al. (2013) Alpha-Synuclein p.H50Q, a Novel Pathogenic Mutation for Parkinson’s Disease. Movement Disorders, 28, 811-813. &lt;br&gt;https://doi.org/10.1002/mds.25421</mixed-citation></ref><ref id="hanspub.43870-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Gómez-Suaga, P., Pérez-Nievas, B.G., Glennon, E.B., et al. (2019) The VAPB-PTPIP51 Endoplasmic Reticulum-Mitochondria Tethering Proteins Are Present in Neuronal Synapses and Regulate Synaptic Activity. Acta Neuropathologica Communications, 7, 35. &lt;br&gt;https://doi.org/10.1186/s40478-019-0688-4</mixed-citation></ref><ref id="hanspub.43870-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Paillusson, S., Gomez-Suaga, P., Stoica, R., et al. (2017) α-Synuclein Binds to the EＲ-Mitochondria Tethering Protein VAPB to Disrupt Ca2+ Homeostasis and Mitochondrial ATP Production. Acta Neuropathologica, 134, 129-149.  
&lt;br&gt;https://doi.org/10.1007/s00401-017-1704-z</mixed-citation></ref><ref id="hanspub.43870-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Oba, T., Saito, T., Asada, A., et al. (2020) Microtubule Affinity-Regulating Kinase 4 with an Alzheimer’s Disease-Related Mutation Promotes Tau Accumulation and Exacerbates Neurodegeneration. Journal of Biological Chemistry, 295, 17138-17147. &lt;br&gt;https://doi.org/10.1074/jbc.RA120.014420</mixed-citation></ref><ref id="hanspub.43870-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Schreiner, B., Hedskog, L., Wiehager, B., et al. (2015) Amyloid-β Peptides Are Generated in Mitochondria-Associated Endoplasmic Reticulum Membranes. Journal of Alzheimer’s Disease, 43, 369-374.  
&lt;br&gt;https://doi.org/10.3233/JAD-132543</mixed-citation></ref><ref id="hanspub.43870-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Lau, D.H.W., Paillusson, S., Hartopp, N., et al. (2020) Disruption of Endoplasmic Reticulum-Mitochondria Tethering Proteins in Post-Mortem Alzheimer’s Disease Brain. Neurobiology of Disease, 14, Article ID: 105020.  
&lt;br&gt;https://doi.org/10.1016/j.nbd.2020.105020</mixed-citation></ref><ref id="hanspub.43870-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Puri, R., Cheng, X.T., Lin, M.Y., et al. (2019) Mul1 Restrains Parkin-Mediated Mitophagy in Mature Neurons by Maintaining ER-Mitochondrial Contacts. Nature Communications, 10, 3645.  
&lt;br&gt;https://doi.org/10.1038/s41467-019-11636-5</mixed-citation></ref></ref-list></back></article>